Table 4.
Variable | Odds Ratio | 95% CI | p-value |
---|---|---|---|
Univariate | |||
| |||
Age, continuous | 1.065 | 1.025–1.107 | 0.0012 |
| |||
KPS | |||
60–80 | 2.40 | 0.98–5.85 | 0.054 |
90–100 | 1.00 | ||
| |||
Hemoglobin (g/dl), continuous | 1.19 | 0.95–1.50 | 0.13 |
| |||
T Stage | |||
T1/T2 | 1.00 | ||
T3/T4 | 1.85 | 0.87–3.93 | 0.11 |
| |||
Tumor Site | |||
Oral cavity/oropharynx | 1.00 | ||
Larynx/hypopharynx | 2.32 | 0.82–6.58 | 0.12 |
| |||
Superior Hypopharynx Dose (Gy), continuous | 1.034 | 1.008–1.062 | 0.011 |
| |||
Inferior Hypopharynx Dose (Gy), continuous | 1.025 | 1.006–1.044 | 0.0079 |
| |||
Multivariate | |||
| |||
Age, continuous | 1.062 | 1.022–1.104 | 0.0021 |
| |||
Inferior Hypopharynx Dose (Gy), Continuous | 1.023† | 1.004–1.043 | 0.016 |
Abbreviations: RL=reference level
Interpretation: An increase in dose of 1 Gy means an increase in the odds of being in the case group by 2%; an increase in dose of 5 Gy means an increase in the odds of being in the case group by 12%; an increase in dose of 10 Gy means an increase in the odds of being in the case group by 26%.